Terezinha P. Munhoz1,2,3 Rosane M. Scheibe1,2 Virgínia M. Schmitt1,2 Venous thromboembolism is a common multifactorial disease associated with acquired and inherited predisposing factors. Several polymorphisms, e.g. factor V Leiden, factor II G20210A and deficiency of antithrombin, protein C and protein S, have been associated with venous thromboembolism. Angiotensin converting-enzyme affects h...

superior vena cava (svc) syndrome is not an uncommon occurrence in patients with malignancy and it is often described as a medical emergency. in majority of the cases, svc syndrome occurs due to mechanical obstruction of the svc by extraluminal compression with primary intrathoracic malignancies. however, intraluminal obstruction due to thrombosis can also produce symptoms and signs of svc synd...

Prophylaxis against venous thromboembolism after elective total hip replacement is routinely recommended. Our preference has been to use mechanical prophylaxis without anticoagulant drugs. A randomised controlled trial was performed to evaluate whether the incidence of post-operative venous thromboembolism was reduced by using pharmacological anticoagulation with either fondaparinux or enoxapar...

BACKGROUND Several novel oral anticoagulants have been studied for the prevention and treatment of venous thromboembolism (VTE) in different patient populations. Clinicians will increasingly encounter scenarios in which they must choose among these and conventional anticoagulants for the treatment of this potentially fatal condition. OBJECTIVE To review the results of Phase III clinical trial...

BACKGROUND The reported incidence of venous thromboembolism (VTE) varies considerably among studies. The primary aim of this study was to describe the incidence of VTE in relation to age and sex. The secondary aim was to describe the risk factor pattern at the time of diagnosis. METHODS This retrospective, population-based cohort study included all adult residents in the County of Västerbotte...

OBJECTIVE To determine the number of hospitalized patients at risk for developing venous thromboembolism (VTE) / deep vein thrombosis (DVT), identifying the most common risk factor and to document the use of thromboprophylaxis. STUDY DESIGN Observational and cross-sectional study. PLACE AND DURATION OF STUDY Chandka Medical College Hospital, Larkana, from October to December 2011. METHODO...

Each year, 25% of all hospitalized patients are affected by venous thromboembolism, a disease comprising deep vein thrombosis and pulmonary embolism, that is responsible for up to 10% of all inpatient deaths (Alikhan, Peters, Wilmott, Cohen, 2004). Used in both the treatment and the prevention of venous thromboembolism, heparin is administered to more than 12 million patients each year in the U...

In ambulatory patients with solid cancer, routine thromboprophylaxis to prevent venous thromboembolism is not recommended. Several risk prediction scores to identify cancer patients at high risk of venous thromboembolism have been proposed, but their clinical usefulness remains a matter of debate. We evaluated and directly compared the performance of the Khorana, Vienna, PROTECHT, and CONKO sco...

The management of patients with venous thromboembolism (VTE) is a common clinical scenario that, for the most part, involves well‑established, evidence‑based treatment pathways. However, important unanswered clinical questions remain that are the focus of ongoing research. The aim of this narrative review is to provide a practical, case‑based approach to the following clinical scenarios in whic...

Background: Current guidelines recommend that full-dose warfarin be continued for 6–12 months after an idiopathic episode of venous thromboembolism (VTE), with a target international normalized ratio (INR) of between 2.0 and 3.0. The annual risk of major hemorrhage in patients prescribed warfarin is 5%–9%, whereas the long-term risk of recurrent VTE after cessation of anticoagulation is 6%–9% p...